Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis.

Moore, C S; Earl, N; Frenette, R; Styhler, A; Mancini, J A; Nicholson, D W; Hebb, A L O; Owens, T; Robertson, G S

Moore, C S; Earl, N; Frenette, R; Styhler, A; Mancini, J A; Nicholson, D W; Hebb, A L O; Owens, T; Robertson, G S.

Affiliation

Moore CS; Department of Pharmacology, Faculty of Medicine, Sir Charles Tupper Bldg., 5850 College St., Halifax, NS B3H 1X5, Canada.

J Pharmacol Exp Ther ; 319(1): 63-72, 2006 Oct.

Article in En | MEDLINE | ID: mdl-16809479

Subject(s)

3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors; Encephalomyelitis, Autoimmune, Experimental/prevention & control; Phosphodiesterase Inhibitors/therapeutic use; Pyridines/therapeutic use; Animals; Body Weight/drug effects; Cyclic Nucleotide Phosphodiesterases, Type 4; Glial Fibrillary Acidic Protein/analysis; Lipopolysaccharides/pharmacology; Mice; Mice, Inbred C57BL; Multiple Sclerosis/drug therapy; Proto-Oncogene Proteins c-fos/analysis; Rolipram/therapeutic use; Spinal Cord/pathology; Tumor Necrosis Factor-alpha/biosynthesis

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phosphodiesterase Inhibitors / Pyridines / 3',5'-Cyclic-AMP Phosphodiesterases / Encephalomyelitis, Autoimmune, Experimental Type of study: Prognostic_studies Limits: Animals Language: En Journal: J Pharmacol Exp Ther Year: 2006 Document type: Article Affiliation country: Canada Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links